29
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Total remission of Tolosa-Hunt Syndrome with single-dose of infliximab Translated title: Remissão total da Síndrome de Tolosa-Hunt com dose única de infliximabe

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Abstract Tolosa-Hunt syndrome is a painful ophthalmoplegia caused by non-specific granulomatous inflammation, corticoid-sensitive, of the cavernous sinus. The etiology is unknown. Recurrences are common. The diagnosis is made by exclusion, and a variety of other diseases involving the orbital apex, superior orbital fissure and cavernous sinus should be ruled out. This study reports a case of a 29-year-old woman, diagnosed with Tolosa-Hunt Syndrome, who presented ophthalmoparesis and orbital pain. She had poor response to corticotherapy and developed colateral effects, so she was treated with single infliximab dose immunosuppression, evolving total remission of the disease.

          Translated abstract

          Resumo A Síndrome de Tolosa-Hunt é uma oftalmoplegia dolorosa causada por uma inflamação granulomatosa não específica, sensível a corticoides, do seio cavernoso. A etiologia é desconhecida. Recorrências são comuns. O diagnóstico é feito por exclusão, devendo ser descartada uma variedade de outras doenças que envolvem o ápice orbitário, fissura orbitária superior e seio cavernoso. O presente estudo trata-se de um relato de caso de uma paciente de 29 anos, diagnosticada com Síndrome de Tolosa-Hunt, que apresentou paresia e dor em região orbital. Obteve resposta pouco efetiva a corticoterapia e desenvolveu efeitos colaterais, por isso foi tratada com dose única de infliximabe, evoluindo com remissão total da doença.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          Infliximab for induction and maintenance therapy for ulcerative colitis.

          Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis. Two randomized, double-blind, placebo-controlled studies--the Active Ulcerative Colitis Trials 1 and 2 (ACT 1 and ACT 2, respectively)--evaluated the efficacy of infliximab for induction and maintenance therapy in adults with ulcerative colitis. In each study, 364 patients with moderate-to-severe active ulcerative colitis despite treatment with concurrent medications received placebo or infliximab (5 mg or 10 mg per kilogram of body weight) intravenously at weeks 0, 2, and 6 and then every eight weeks through week 46 (in ACT 1) or week 22 (in ACT 2). Patients were followed for 54 weeks in ACT 1 and 30 weeks in ACT 2. In ACT 1, 69 percent of patients who received 5 mg of infliximab and 61 percent of those who received 10 mg had a clinical response at week 8, as compared with 37 percent of those who received placebo (P<0.001 for both comparisons with placebo). A response was defined as a decrease in the Mayo score of at least 3 points and at least 30 percent, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or an absolute rectal-bleeding subscore of 0 or 1. In ACT 2, 64 percent of patients who received 5 mg of infliximab and 69 percent of those who received 10 mg had a clinical response at week 8, as compared with 29 percent of those who received placebo (P<0.001 for both comparisons with placebo). In both studies, patients who received infliximab were more likely to have a clinical response at week 30 (P< or =0.002 for all comparisons). In ACT 1, more patients who received 5 mg or 10 mg of infliximab had a clinical response at week 54 (45 percent and 44 percent, respectively) than did those who received placebo (20 percent, P<0.001 for both comparisons). Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo. (ClinicalTrials.gov numbers, NCT00036439 and NCT00096655.) Copyright 2005 Massachusetts Medical Society.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

            Permanent loss of vision resulting from relapsing ocular inflammation occurs frequently in patients with Behçet's disease, despite intensive, chronic immunosuppressive therapy. Since tumour necrosis factor (TNF) might have an important pathogenetic role in Behçet's disease, we decided to give a single infusion of infliximab-a monoclonal antibody against TNF-to five patients with relapsing panuveitis, at the immediate onset of last relapse. Remission of ocular inflammation was evident within the first 24 h, and complete suppression was seen 7 days after treatment in all patients. No side-effects were noted. We suggest that infliximab is a rapid and effective new therapy for sight-threatening ocular inflammation in Behçet's disease.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Periarteritic lesions of the carotid siphon with the clinical features of a carotid infraclinoidal aneurysm.

              E Tolosa (1954)
                Bookmark

                Author and article information

                Contributors
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Journal
                rbof
                Revista Brasileira de Oftalmologia
                Rev. bras.oftalmol.
                Sociedade Brasileira de Oftalmologia (Rio de Janeiro, RJ, Brazil )
                0034-7280
                1982-8551
                January 2020
                : 79
                : 1
                : 59-62
                Affiliations
                [1] Recife PE orgnameCentro Universitário Maurício de Nassau orgdiv1Acadêmico de Medicina Brasil
                [2] Recife PE orgnameServiço Oftalmológico de Pernambuco orgdiv1Setor de Uveíte Brasil
                [4] Campina Grande Paraíba orgnameFaculdade de Ciências Médicas de Campina Grande orgdiv1Acadêmico de Medicina Brazil
                [3] Recife PE orgnameServiço Oftalmológico de Pernambuco orgdiv1Setor de Catarata Brasil
                [5] Recife Pernambuco orgnameUniversidade Federal de Pernambuco orgdiv1Setor de Neuro-Oftalmologia Brazil
                Article
                S0034-72802020000100059 S0034-7280(20)07900100059
                10.5935/0034-7280.20200012
                f9958b44-411d-470f-9ca1-80ccdad55ed4

                This work is licensed under a Creative Commons Attribution 4.0 International License.

                History
                : 18 February 2019
                : 10 July 2019
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 17, Pages: 4
                Product

                SciELO Brazil

                Categories
                Case Report

                Dor,Tolosa-Hunt Syndrome,Ophthalmoplegia,Infliximab,Pain,Síndrome de Tolosa-Hunt,Oftalmoplegia,Infliximabe

                Comments

                Comment on this article